ARWR Arrowhead Pharmaceuticals, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
14:27
Oct 14
Oct 14
03:39
Jan 07
Jan 07
3PRO TV
Obesity and biotech momentum remain strong
Eli Lilly joined Novo Nordisk's China obesity-drug price cuts yet rose, Arrowhead jumped on positive diabetes-obesity data, and biotech small caps are moving on FDA approvals ahead of the JP Morgan Healthcare Conference. Obesity and biotech momentum remain strong.
ARWR
Arrowhead Pharmaceuticals, Inc.
Long
—
—
22:04
Jan 06
Jan 06
3PRO TV
Arrowhead data sparks double-digit surge.
Arrowhead Pharmaceuticals showed positive efficacy for a diabetes-with-obesity treatment and the stock surged double digits, suggesting small biotech companies can keep delivering on obesity treatment potential.
ARWR
Arrowhead Pharmaceuticals, Inc.
Long
1ST
—
—
About ARWR Investor Commentary
Across the available history and selected sources, Buzzberg tracks ARWR (Arrowhead Pharmaceuticals, Inc.) across 4 sources: 3 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Latest voices: psyduckcapital, Park Myung-seok.